A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.

Deepak Kilari,Aniko Szabo,Kathryn A. Bylow,Robert S. Alter,Ariel Ann Nelson,Emily Lemke,William A. Hall,Scott Johnson,Peter Langenstroer,Kenneth Jacobsohn,Nancy B. Davis,Chunkit Fung,Matthew I. Milowsky

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.

2021

Deepak Kilari
Aniko Szabo
Kathryn A. Bylow
Robert S. Alter
Ariel Ann Nelson
Emily Lemke
William A. Hall
Scott Johnson
Peter Langenstroer
Kenneth Jacobsohn
Nancy B. Davis
Chunkit Fung
Matthew I. Milowsky

TPS4591Background: ABACUS and PURE-01 trials demonstrated the activity of single agent atezolizumab and pembrolizumab respectively as neoadjuvant therapy for muscle invasive urothelial carcinoma (M...

Keywords:

Medicine
Internal medicine
muscle invasive
Pembrolizumab
Phases of clinical research
Neoadjuvant therapy
Cabozantinib
Oncology
Atezolizumab
Bladder cancer
neoadjuvant treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations